Africa: Twice-Yearly Lenacapavir Continues to Show Strong HIV Prevention Results
"Islatravir-lenacapavir has the potential to offer people living with HIV an oral, long-acting alternative to the current paradigm of daily dosing."He said the Phase III ISLEND-1 and ISLEND-2 trials evaluated a once-weekly oral single-tablet regimen combining islatravir and lenacapavir, which has the potential to become the first complete weekly oral treatment for virologically suppressed adults living with HIV.
Researchers unveiled encouraging results from two Phase III trials evaluating what could become the world's first once-weekly oral HIV treatment regimen for people whose virus is already suppressed.
This is a summary of the original articles listed below. Always read the source articles for the full context. GhanaSummary does not create or modify the news — we summarise and link to original publishers.
